Figure 4

Outcome to bevacizumab-containing therapy in CRC by serum VEGF (n=34), tumour MVD and PC (n=17). (A) PFS by serum VEGF. (B) OS by serum VEGF. (C) PFS by MVD. (D) OS by MVD. (E) PFS by PC. (F) OS by PC. VEGF, vascular endothelial growth factor, MVD, microvessel density, PC, pericyte coverage.